NO20052153L - Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. - Google Patents
Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer.Info
- Publication number
- NO20052153L NO20052153L NO20052153A NO20052153A NO20052153L NO 20052153 L NO20052153 L NO 20052153L NO 20052153 A NO20052153 A NO 20052153A NO 20052153 A NO20052153 A NO 20052153A NO 20052153 L NO20052153 L NO 20052153L
- Authority
- NO
- Norway
- Prior art keywords
- piperazine
- neurological diseases
- piperidine derivatives
- treatment
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41613402P | 2002-10-03 | 2002-10-03 | |
| PCT/US2003/031080 WO2004031148A1 (fr) | 2002-10-03 | 2003-10-02 | Piperazine et derives de piperidine permettant de traiter des maladies neurologiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20052153L true NO20052153L (no) | 2005-05-31 |
Family
ID=32069937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052153A NO20052153L (no) | 2002-10-03 | 2005-05-02 | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040180880A1 (fr) |
| EP (1) | EP1546103B1 (fr) |
| JP (1) | JP2006504717A (fr) |
| KR (1) | KR20050047132A (fr) |
| CN (1) | CN100395236C (fr) |
| AT (1) | ATE425967T1 (fr) |
| AU (1) | AU2003299145A1 (fr) |
| CA (1) | CA2500672A1 (fr) |
| DE (1) | DE60326742D1 (fr) |
| ES (1) | ES2324293T3 (fr) |
| MX (1) | MXPA05003471A (fr) |
| NO (1) | NO20052153L (fr) |
| PL (1) | PL376149A1 (fr) |
| RU (1) | RU2005113247A (fr) |
| TW (1) | TW200533653A (fr) |
| WO (1) | WO2004031148A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| WO2007018459A1 (fr) * | 2005-08-08 | 2007-02-15 | Astrazeneca Ab | Agents thérapeutiques |
| US7943622B2 (en) | 2006-06-06 | 2011-05-17 | Cornerstone Therapeutics, Inc. | Piperazines, pharmaceutical compositions and methods of use thereof |
| BRPI1013763A2 (pt) * | 2009-04-16 | 2015-08-25 | Takeda Pharmaceutical | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto |
| RU2486918C1 (ru) * | 2011-10-25 | 2013-07-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ стимулирования восстановления периферической иннервации тканей с помощью векторных конструкций |
| AU2016348549B2 (en) | 2015-11-02 | 2020-07-23 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound |
| CN109923116B (zh) | 2016-11-02 | 2022-12-06 | 詹森药业有限公司 | 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物 |
| EA039102B1 (ru) | 2016-11-02 | 2021-12-03 | Янссен Фармацевтика Нв | Соединения [1,2,4]триазоло[1,5-a]пиримидина в качестве ингибиторов pde2 |
| CA3038913A1 (fr) | 2016-11-02 | 2018-05-11 | Janssen Pharmaceutica Nv | Composes de [1,2,4] triazolo [1,5-a] pyrimidine en tant qu'inhibiteurs de pde2 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2597100A1 (fr) * | 1986-01-21 | 1987-10-16 | Nippon Shinyaku Co Ltd | Derives du pyroglutamide |
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| US5811434A (en) * | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| NZ502820A (en) * | 1997-08-29 | 2002-10-25 | Vertex Pharma | Heteroaryl or aryl substituted carboxylic acid or carboxamide derivatives optionally substituted with a sulphonamido group |
| US6331537B1 (en) * | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| US6264991B1 (en) * | 1998-08-18 | 2001-07-24 | Southern Research Institute | Compositions and methods for treating intracellular infections |
| CZ20022720A3 (cs) * | 2000-02-11 | 2002-11-13 | Vertex Pharmaceuticals Incorporated | Deriváty piperazinu a piperidinu pro pouľití při léčení a prevenci poąkozených neuronů |
| US20040034019A1 (en) * | 2002-08-08 | 2004-02-19 | Ronald Tomlinson | Piperazine and piperidine derivatives |
-
2003
- 2003-10-02 US US10/677,631 patent/US20040180880A1/en not_active Abandoned
- 2003-10-02 CN CNB2003801041723A patent/CN100395236C/zh not_active Expired - Fee Related
- 2003-10-02 DE DE60326742T patent/DE60326742D1/de not_active Expired - Lifetime
- 2003-10-02 ES ES03756899T patent/ES2324293T3/es not_active Expired - Lifetime
- 2003-10-02 RU RU2005113247/04A patent/RU2005113247A/ru not_active Application Discontinuation
- 2003-10-02 EP EP03756899A patent/EP1546103B1/fr not_active Expired - Lifetime
- 2003-10-02 PL PL03376149A patent/PL376149A1/xx not_active Application Discontinuation
- 2003-10-02 JP JP2004541991A patent/JP2006504717A/ja active Pending
- 2003-10-02 AU AU2003299145A patent/AU2003299145A1/en not_active Abandoned
- 2003-10-02 CA CA002500672A patent/CA2500672A1/fr not_active Abandoned
- 2003-10-02 KR KR1020057005779A patent/KR20050047132A/ko not_active Application Discontinuation
- 2003-10-02 AT AT03756899T patent/ATE425967T1/de not_active IP Right Cessation
- 2003-10-02 WO PCT/US2003/031080 patent/WO2004031148A1/fr active Application Filing
- 2003-10-02 MX MXPA05003471A patent/MXPA05003471A/es not_active Application Discontinuation
-
2004
- 2004-04-05 TW TW093109385A patent/TW200533653A/zh unknown
-
2005
- 2005-05-02 NO NO20052153A patent/NO20052153L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| RU2005113247A (ru) | 2006-01-20 |
| EP1546103B1 (fr) | 2009-03-18 |
| TW200533653A (en) | 2005-10-16 |
| ES2324293T3 (es) | 2009-08-04 |
| EP1546103A1 (fr) | 2005-06-29 |
| US20040180880A1 (en) | 2004-09-16 |
| KR20050047132A (ko) | 2005-05-19 |
| AU2003299145A1 (en) | 2004-04-23 |
| CN100395236C (zh) | 2008-06-18 |
| CN1717390A (zh) | 2006-01-04 |
| MXPA05003471A (es) | 2005-07-01 |
| WO2004031148A1 (fr) | 2004-04-15 |
| DE60326742D1 (de) | 2009-04-30 |
| PL376149A1 (en) | 2005-12-27 |
| ATE425967T1 (de) | 2009-04-15 |
| JP2006504717A (ja) | 2006-02-09 |
| CA2500672A1 (fr) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2002002596A0 (en) | Piperazine and piperidine derivatives. | |
| NO20052153L (no) | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. | |
| TW200510334A (en) | Preraration and use of aryl alkyl acid derivatives for the treatment of obesity | |
| ATE362363T1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
| DE60026155D1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| GEP20084420B (en) | Use of imidazole compounds for the treatment of neurodegenerative disorders | |
| ATE381935T1 (de) | Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen | |
| MY140132A (en) | Thiazolidin-4-one derivatives for use in the treatment of anemias | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| DE60029799D1 (de) | Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| DE60307749D1 (de) | Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem | |
| DE602007011975D1 (de) | Thiadiazolderivate zur behandlung neurodegenerativer krankheiten | |
| ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| DE602005015697D1 (de) | Te zur behandlung von alzheimer-krankheit | |
| DOP2003000621A (es) | Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| ATE464048T1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| HK1074840A1 (en) | Novel dithiolopyrrolones with therapeutic activity | |
| ATE380551T1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| DE602004022423D1 (de) | Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz | |
| DE10391491D2 (de) | Verwendung von Pyrimidinnukleotiden zur Behandlung von Schädigungen des peripheren Nervensystems | |
| ATE350034T1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
| HK1082727A1 (en) | 2" oxo-voruscharin and derivatives thereof | |
| DE60313344D1 (de) | Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |